In this series, we bring together the foremost medical experts to enlighten and empower women facing a diagnosis of HR+/HER2- metastatic breast cancer. They provide answers to your top questions and share insights and practical tips that help you move ahead with clarity and confidence.
Dana-Farber Cancer Institute oncologist Sara Tolaney, MD, MPH, explains treatment options for HR+/HER2- metastatic breast cancer, including aromatase inhibitors and CDK4/6 inhibitors.
See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.